The Functional Difference of Dendritic Cells in HBeAg Negative Chronic Hepatitis B Patients with Three Different Spleen Deficiency Syndromes and the Therapeutic Evaluation of Chinese Medicine Intervention Based on Syndrome Differentiation

Table 4

The comparison of DCs biomarkers, IL-10, and IL-12 levels in HBeAg negative CHB patients before and after treatment.

Group	CD80 (%)	CD86 (%)	CD1a (%)	HLA-DR (%)	IL-10 (pg/mL)	IL-12 (pg/mL)
K	65.03±9.25	75.60±7.26	63.21±15.43	59.21±15.14	14.31±6.22	36.67±8.23
A
Before	12.04±10.54^#&	49.51±13.35^#	32.37±10.06^#&	52.32±16.01^&	47.43±24.59^#&	16.25±6.12^#&
After	35.20±10.47^∗	64.08±11.21^∗	45.15±11.31^∗	53.83±12.99	24.88±12.06^∗	26.12±9.32^∗
B
Before	9.13±6.95^#	51.38±13.74^#	30.11±10.58^#&	43.26±16.35^#	51.43±24.41^#	14.49±5.03^#&
After	42.66±13.09^▲∗	68.14±15.97^∗	44.52±10.63^∗	57.34±10.68^∗	23.13±11.40^∗	25.49±8.42^∗
C
Before	6.01±3.32^#	43.54±20.06^#	20.24±9.37^#	38.20±14.12^#	65.54±27.18^#	8.69±4.13^#
After	28.46±7.90^∗	70.86±18.42^∗	38.43±12.19^∗	55.81±13.88^∗	28.56±9.78^∗	20.54±7.47^∗

^#𝑃<0.01, compared to group K before treatment; ^&𝑃<0.05, compared to group C before treatment; ^∗𝑃<0.05, compared to before treatment in each group; ^▲𝑃<0.05, compared to group C after treatment.